|
Estimated haplotype frequencies of HLA class II loci |
||||||||
| DRB1-DQA1-DQB1 haplotype |
% |
|||||||
|
|
||||||||
| Controls |
PM |
DM |
Other antibodiesa |
|||||
|
|
||||||||
| Overall |
Overall |
AS |
Mi-2 |
PM-Scl |
U1-RNP |
SRP |
||
|
|
||||||||
| 2n = 284 |
2n = 220 |
2n = 208 |
2n = 98 |
2n = 36 |
2n = 22 |
2n = 24 |
2n = 12 |
|
|
|
||||||||
| 04-03-03 |
20.4 |
16.4 |
19.1 |
17.3 |
13.8 |
4.5 |
37.5 |
0 |
| 03-05-02b |
16.5 |
33.6 |
24.5 |
43.9 |
8.3 |
54.5 |
12.5 |
4.1 |
| 02-01-06 |
13.7 |
9.1 |
9.6 |
10.2 |
8.3 |
4.5 |
20.8 |
25.0 |
| 01-01-05 |
10.6 |
11.8 |
13.5 |
7.1 |
22.2 |
9.1 |
16.7 |
8.3 |
| 13-01-06 |
10.2 |
6.4 |
5.8 |
6.1 |
0 |
4.5 |
1.0 |
8.3 |
| 07-02-02c |
9.2 |
4.1 |
13.9 |
7.1 |
33.3 |
18.2 |
0 |
0 |
| 11-05-03 |
4.6 |
7.3 |
5.3 |
2.0 |
5.6 |
0 |
0 |
16.7 |
| 07-02-03 |
3.9 |
0.4 |
3.8 |
0 |
5.6 |
0 |
1.0 |
0 |
|
Probabilities stated are corrected for multiple comparisons. Haplotypes found in less than 3% of controls are excluded from the table. aPolymyositis and dermatomyositis patients combined. bPM versus controls, p = 1.1 × 10-4, odds ratio (OR) 2.6 (95% confidence interval (CI) 1.6–4.0); AS versus controls, p = 7 × 10-10, OR 4.8 (CI 2.8–8.3); PM-Scl versus controls, p = 0.001, OR 6.1 (CI 2.2–16.5). cPM versus DM, p = 0.004, OR 0.3 (CI 0.1–0.6); Mi-2 versus controls, p = 0.002, OR 4.9 (CI 2.0–11.6). AS, anti-tRNA synthetase positive; DM, dermatomyositis; PM, polymyositis. | ||||||||
Chinoy et al. Arthritis Research & Therapy 2006 8:R13 doi:10.1186/ar1862 |
||||||||